Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

Lassman, A. B., Pugh, S. L., Wang, T. J. C., Aldape, K., Gan, H. K., Preusser, M., Vogelbaum, M. A., Sulman, E. P., Won, M., Zhang, P., Moazami, G., Macsai, M. S., Gilbert, M. R., Bain, E. E., Blot, V., Ansell, P. J., Samanta, S., Kundu, M. G., Armstrong, T. S., … Mehta, M. P. (2022). Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology, 25(2), 339–350. https://doi.org/10.1093/neuonc/noac173
Authors:
Andrew B Lassman
Stephanie L Pugh
Tony J C Wang
Kenneth Aldape
Hui K Gan
Matthias Preusser
Michael A Vogelbaum
Erik P Sulman
Minhee Won
Peixin Zhang
Golnaz Moazami
Marian S Macsai
Mark R Gilbert
Earle E Bain
Vincent Blot
Peter J Ansell
Suvajit Samanta
Madan G Kundu
Terri S Armstrong
Jeffrey S Wefel
Clemens Seidel
Filip Y de Vos
Sigmund Hsu
Andrés F Cardona
Giuseppe Lombardi
Dmitry Bentsion
Richard A Peterson
Craig Gedye
Véronique Bourg
Antje Wick
Walter J Curran
Minesh P Mehta
Affiliated Authors:
Andrew B Lassman
Tony J C Wang
Golnaz Moazami
Columbia Affiliation:
Subjects:
Glioblastoma (MeSH)
Brain Neoplasms (MeSH)
Author Keywords:
antibody drug conjugate
depatuxizumab mafodotin
egfr
glioblastoma
phase iii
elink
Publication Type:
Article
Unique ID:
10.1093/neuonc/noac173
PMID:
35849035
DOI:
10.1093/neuonc/noac173
Journal:
Neuro-Oncology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: